A protein derived from scorpion toxin being used to spearhead Chimeric Therapeutics’ cell therapy assault on brain cancer cells has delivered encouraging early results from a study being conducted at the world-famous City of Hope Hospital in Los Angeles.
Patients in the study responded well to the simultaneous introduction of the ASX-listed company’s cell therapy that was targeted directly…
